nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosentan—ABCB11—Paclitaxel—ovarian cancer	0.245	0.434	CbGbCtD
Bosentan—ABCB11—Doxorubicin—ovarian cancer	0.132	0.234	CbGbCtD
Bosentan—CYP3A4—Topotecan—ovarian cancer	0.0508	0.0901	CbGbCtD
Bosentan—CYP2C9—Paclitaxel—ovarian cancer	0.0432	0.0767	CbGbCtD
Bosentan—CYP3A4—Vinorelbine—ovarian cancer	0.0358	0.0635	CbGbCtD
Bosentan—CYP3A4—Paclitaxel—ovarian cancer	0.0251	0.0446	CbGbCtD
Bosentan—CYP3A4—Docetaxel—ovarian cancer	0.0182	0.0323	CbGbCtD
Bosentan—CYP3A4—Doxorubicin—ovarian cancer	0.0136	0.024	CbGbCtD
Bosentan—EDNRB—myometrium—ovarian cancer	0.00729	0.0897	CbGeAlD
Bosentan—EDNRA—myometrium—ovarian cancer	0.00602	0.0742	CbGeAlD
Bosentan—EDNRB—uterine cervix—ovarian cancer	0.00567	0.0698	CbGeAlD
Bosentan—EDNRB—decidua—ovarian cancer	0.0054	0.0665	CbGeAlD
Bosentan—EDNRB—endometrium—ovarian cancer	0.00513	0.0631	CbGeAlD
Bosentan—EDNRB—uterus—ovarian cancer	0.00473	0.0582	CbGeAlD
Bosentan—EDNRA—uterine cervix—ovarian cancer	0.00469	0.0577	CbGeAlD
Bosentan—EDNRA—decidua—ovarian cancer	0.00447	0.055	CbGeAlD
Bosentan—EDNRA—endometrium—ovarian cancer	0.00424	0.0522	CbGeAlD
Bosentan—EDNRA—uterus—ovarian cancer	0.00391	0.0481	CbGeAlD
Bosentan—EDNRB—female gonad—ovarian cancer	0.00387	0.0476	CbGeAlD
Bosentan—EDNRB—vagina—ovarian cancer	0.00384	0.0473	CbGeAlD
Bosentan—EDNRB—testis—ovarian cancer	0.00343	0.0422	CbGeAlD
Bosentan—EDNRA—female gonad—ovarian cancer	0.0032	0.0393	CbGeAlD
Bosentan—EDNRA—vagina—ovarian cancer	0.00318	0.0391	CbGeAlD
Bosentan—EDNRA—testis—ovarian cancer	0.00283	0.0349	CbGeAlD
Bosentan—ABCB11—testis—ovarian cancer	0.00277	0.0341	CbGeAlD
Bosentan—EDNRB—lymph node—ovarian cancer	0.00248	0.0306	CbGeAlD
Bosentan—EDNRA—lymph node—ovarian cancer	0.00205	0.0253	CbGeAlD
Bosentan—CYP2C9—female reproductive system—ovarian cancer	0.00116	0.0143	CbGeAlD
Bosentan—CYP3A4—female reproductive system—ovarian cancer	0.000886	0.0109	CbGeAlD
Bosentan—Weight increased—Epirubicin—ovarian cancer	0.000223	0.000694	CcSEcCtD
Bosentan—Loss of consciousness—Docetaxel—ovarian cancer	0.000223	0.000692	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.000222	0.000691	CcSEcCtD
Bosentan—Weight decreased—Epirubicin—ovarian cancer	0.000222	0.00069	CcSEcCtD
Bosentan—Hyperglycaemia—Epirubicin—ovarian cancer	0.000221	0.000688	CcSEcCtD
Bosentan—Cough—Docetaxel—ovarian cancer	0.000221	0.000688	CcSEcCtD
Bosentan—Angina pectoris—Doxorubicin—ovarian cancer	0.000221	0.000687	CcSEcCtD
Bosentan—Insomnia—Paclitaxel—ovarian cancer	0.000221	0.000686	CcSEcCtD
Bosentan—Pneumonia—Epirubicin—ovarian cancer	0.00022	0.000684	CcSEcCtD
Bosentan—Paraesthesia—Paclitaxel—ovarian cancer	0.000219	0.000681	CcSEcCtD
Bosentan—Infestation NOS—Epirubicin—ovarian cancer	0.000219	0.00068	CcSEcCtD
Bosentan—Infestation—Epirubicin—ovarian cancer	0.000219	0.00068	CcSEcCtD
Bosentan—Bronchitis—Doxorubicin—ovarian cancer	0.000218	0.000679	CcSEcCtD
Bosentan—Dyspnoea—Paclitaxel—ovarian cancer	0.000218	0.000676	CcSEcCtD
Bosentan—Somnolence—Paclitaxel—ovarian cancer	0.000217	0.000674	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Epirubicin—ovarian cancer	0.000217	0.000674	CcSEcCtD
Bosentan—Arthralgia—Docetaxel—ovarian cancer	0.000216	0.000671	CcSEcCtD
Bosentan—Chest pain—Docetaxel—ovarian cancer	0.000216	0.000671	CcSEcCtD
Bosentan—Nausea—Vinorelbine—ovarian cancer	0.000215	0.00067	CcSEcCtD
Bosentan—Renal failure—Epirubicin—ovarian cancer	0.000215	0.000668	CcSEcCtD
Bosentan—Dyspepsia—Paclitaxel—ovarian cancer	0.000215	0.000668	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000214	0.000666	CcSEcCtD
Bosentan—Stomatitis—Epirubicin—ovarian cancer	0.000213	0.000663	CcSEcCtD
Bosentan—Jaundice—Epirubicin—ovarian cancer	0.000213	0.000663	CcSEcCtD
Bosentan—Conjunctivitis—Epirubicin—ovarian cancer	0.000213	0.000661	CcSEcCtD
Bosentan—Urinary tract infection—Epirubicin—ovarian cancer	0.000213	0.000661	CcSEcCtD
Bosentan—Dysuria—Doxorubicin—ovarian cancer	0.000212	0.00066	CcSEcCtD
Bosentan—Neutropenia—Doxorubicin—ovarian cancer	0.000212	0.00066	CcSEcCtD
Bosentan—Decreased appetite—Paclitaxel—ovarian cancer	0.000212	0.000659	CcSEcCtD
Bosentan—Dry mouth—Docetaxel—ovarian cancer	0.000211	0.000656	CcSEcCtD
Bosentan—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000211	0.000656	CcSEcCtD
Bosentan—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000211	0.000655	CcSEcCtD
Bosentan—Fatigue—Paclitaxel—ovarian cancer	0.00021	0.000654	CcSEcCtD
Bosentan—Pollakiuria—Doxorubicin—ovarian cancer	0.00021	0.000652	CcSEcCtD
Bosentan—Pain—Paclitaxel—ovarian cancer	0.000209	0.000649	CcSEcCtD
Bosentan—Constipation—Paclitaxel—ovarian cancer	0.000209	0.000649	CcSEcCtD
Bosentan—Haematuria—Epirubicin—ovarian cancer	0.000209	0.000648	CcSEcCtD
Bosentan—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000207	0.000643	CcSEcCtD
Bosentan—Oedema—Docetaxel—ovarian cancer	0.000207	0.000643	CcSEcCtD
Bosentan—Anaphylactic shock—Docetaxel—ovarian cancer	0.000207	0.000643	CcSEcCtD
Bosentan—Weight increased—Doxorubicin—ovarian cancer	0.000207	0.000642	CcSEcCtD
Bosentan—Epistaxis—Epirubicin—ovarian cancer	0.000206	0.000641	CcSEcCtD
Bosentan—Infection—Docetaxel—ovarian cancer	0.000205	0.000639	CcSEcCtD
Bosentan—Weight decreased—Doxorubicin—ovarian cancer	0.000205	0.000638	CcSEcCtD
Bosentan—Sinusitis—Epirubicin—ovarian cancer	0.000205	0.000638	CcSEcCtD
Bosentan—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000205	0.000637	CcSEcCtD
Bosentan—Pneumonia—Doxorubicin—ovarian cancer	0.000204	0.000633	CcSEcCtD
Bosentan—Shock—Docetaxel—ovarian cancer	0.000203	0.000633	CcSEcCtD
Bosentan—Nervous system disorder—Docetaxel—ovarian cancer	0.000203	0.000631	CcSEcCtD
Bosentan—Thrombocytopenia—Docetaxel—ovarian cancer	0.000202	0.00063	CcSEcCtD
Bosentan—Infestation NOS—Doxorubicin—ovarian cancer	0.000202	0.000629	CcSEcCtD
Bosentan—Infestation—Doxorubicin—ovarian cancer	0.000202	0.000629	CcSEcCtD
Bosentan—Tachycardia—Docetaxel—ovarian cancer	0.000202	0.000628	CcSEcCtD
Bosentan—Skin disorder—Docetaxel—ovarian cancer	0.000201	0.000625	CcSEcCtD
Bosentan—Stevens-Johnson syndrome—Doxorubicin—ovarian cancer	0.000201	0.000624	CcSEcCtD
Bosentan—Bradycardia—Epirubicin—ovarian cancer	0.0002	0.000621	CcSEcCtD
Bosentan—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.0002	0.00062	CcSEcCtD
Bosentan—Renal failure—Doxorubicin—ovarian cancer	0.000199	0.000619	CcSEcCtD
Bosentan—Haemoglobin—Epirubicin—ovarian cancer	0.000197	0.000614	CcSEcCtD
Bosentan—Jaundice—Doxorubicin—ovarian cancer	0.000197	0.000613	CcSEcCtD
Bosentan—Stomatitis—Doxorubicin—ovarian cancer	0.000197	0.000613	CcSEcCtD
Bosentan—Anorexia—Docetaxel—ovarian cancer	0.000197	0.000613	CcSEcCtD
Bosentan—Conjunctivitis—Doxorubicin—ovarian cancer	0.000197	0.000612	CcSEcCtD
Bosentan—Urinary tract infection—Doxorubicin—ovarian cancer	0.000197	0.000612	CcSEcCtD
Bosentan—Hepatitis—Epirubicin—ovarian cancer	0.000196	0.00061	CcSEcCtD
Bosentan—Haemorrhage—Epirubicin—ovarian cancer	0.000196	0.00061	CcSEcCtD
Bosentan—Hypoaesthesia—Epirubicin—ovarian cancer	0.000195	0.000607	CcSEcCtD
Bosentan—Urinary tract disorder—Epirubicin—ovarian cancer	0.000194	0.000603	CcSEcCtD
Bosentan—Urticaria—Paclitaxel—ovarian cancer	0.000194	0.000603	CcSEcCtD
Bosentan—Oedema peripheral—Epirubicin—ovarian cancer	0.000193	0.000601	CcSEcCtD
Bosentan—Hypotension—Docetaxel—ovarian cancer	0.000193	0.000601	CcSEcCtD
Bosentan—Haematuria—Doxorubicin—ovarian cancer	0.000193	0.0006	CcSEcCtD
Bosentan—Abdominal pain—Paclitaxel—ovarian cancer	0.000193	0.0006	CcSEcCtD
Bosentan—Body temperature increased—Paclitaxel—ovarian cancer	0.000193	0.0006	CcSEcCtD
Bosentan—Urethral disorder—Epirubicin—ovarian cancer	0.000192	0.000598	CcSEcCtD
Bosentan—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000191	0.000595	CcSEcCtD
Bosentan—Epistaxis—Doxorubicin—ovarian cancer	0.000191	0.000593	CcSEcCtD
Bosentan—Sinusitis—Doxorubicin—ovarian cancer	0.00019	0.00059	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000188	0.000586	CcSEcCtD
Bosentan—Insomnia—Docetaxel—ovarian cancer	0.000187	0.000582	CcSEcCtD
Bosentan—Paraesthesia—Docetaxel—ovarian cancer	0.000186	0.000577	CcSEcCtD
Bosentan—Erythema multiforme—Epirubicin—ovarian cancer	0.000186	0.000577	CcSEcCtD
Bosentan—Bradycardia—Doxorubicin—ovarian cancer	0.000185	0.000575	CcSEcCtD
Bosentan—Dyspnoea—Docetaxel—ovarian cancer	0.000184	0.000573	CcSEcCtD
Bosentan—Somnolence—Docetaxel—ovarian cancer	0.000184	0.000572	CcSEcCtD
Bosentan—Eye disorder—Epirubicin—ovarian cancer	0.000183	0.000571	CcSEcCtD
Bosentan—Tinnitus—Epirubicin—ovarian cancer	0.000183	0.000569	CcSEcCtD
Bosentan—Haemoglobin—Doxorubicin—ovarian cancer	0.000183	0.000568	CcSEcCtD
Bosentan—Cardiac disorder—Epirubicin—ovarian cancer	0.000182	0.000567	CcSEcCtD
Bosentan—Flushing—Epirubicin—ovarian cancer	0.000182	0.000567	CcSEcCtD
Bosentan—Dyspepsia—Docetaxel—ovarian cancer	0.000182	0.000566	CcSEcCtD
Bosentan—Haemorrhage—Doxorubicin—ovarian cancer	0.000182	0.000565	CcSEcCtD
Bosentan—Hepatitis—Doxorubicin—ovarian cancer	0.000182	0.000565	CcSEcCtD
Bosentan—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000181	0.000562	CcSEcCtD
Bosentan—Decreased appetite—Docetaxel—ovarian cancer	0.00018	0.000559	CcSEcCtD
Bosentan—Hypersensitivity—Paclitaxel—ovarian cancer	0.00018	0.000559	CcSEcCtD
Bosentan—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000179	0.000558	CcSEcCtD
Bosentan—Oedema peripheral—Doxorubicin—ovarian cancer	0.000179	0.000556	CcSEcCtD
Bosentan—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000179	0.000555	CcSEcCtD
Bosentan—Fatigue—Docetaxel—ovarian cancer	0.000178	0.000554	CcSEcCtD
Bosentan—Angiopathy—Epirubicin—ovarian cancer	0.000178	0.000554	CcSEcCtD
Bosentan—Urethral disorder—Doxorubicin—ovarian cancer	0.000178	0.000554	CcSEcCtD
Bosentan—Immune system disorder—Epirubicin—ovarian cancer	0.000177	0.000551	CcSEcCtD
Bosentan—Mediastinal disorder—Epirubicin—ovarian cancer	0.000177	0.00055	CcSEcCtD
Bosentan—Constipation—Docetaxel—ovarian cancer	0.000177	0.00055	CcSEcCtD
Bosentan—Pain—Docetaxel—ovarian cancer	0.000177	0.00055	CcSEcCtD
Bosentan—Chills—Epirubicin—ovarian cancer	0.000176	0.000548	CcSEcCtD
Bosentan—Asthenia—Paclitaxel—ovarian cancer	0.000175	0.000544	CcSEcCtD
Bosentan—CYP2C9—Arachidonic acid metabolism—CYP1B1—ovarian cancer	0.000173	0.00513	CbGpPWpGaD
Bosentan—Pruritus—Paclitaxel—ovarian cancer	0.000173	0.000537	CcSEcCtD
Bosentan—Mental disorder—Epirubicin—ovarian cancer	0.000172	0.000535	CcSEcCtD
Bosentan—Erythema multiforme—Doxorubicin—ovarian cancer	0.000172	0.000534	CcSEcCtD
Bosentan—EDNRA—Endothelins—HRAS—ovarian cancer	0.000171	0.00508	CbGpPWpGaD
Bosentan—Erythema—Epirubicin—ovarian cancer	0.000171	0.000531	CcSEcCtD
Bosentan—Malnutrition—Epirubicin—ovarian cancer	0.000171	0.000531	CcSEcCtD
Bosentan—Eye disorder—Doxorubicin—ovarian cancer	0.00017	0.000528	CcSEcCtD
Bosentan—Tinnitus—Doxorubicin—ovarian cancer	0.000169	0.000527	CcSEcCtD
Bosentan—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000169	0.000526	CcSEcCtD
Bosentan—Flushing—Doxorubicin—ovarian cancer	0.000169	0.000524	CcSEcCtD
Bosentan—Cardiac disorder—Doxorubicin—ovarian cancer	0.000169	0.000524	CcSEcCtD
Bosentan—EDNRB—Peptide ligand-binding receptors—CXCL8—ovarian cancer	0.000168	0.005	CbGpPWpGaD
Bosentan—Flatulence—Epirubicin—ovarian cancer	0.000168	0.000524	CcSEcCtD
Bosentan—Diarrhoea—Paclitaxel—ovarian cancer	0.000167	0.000519	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—HSD17B6—ovarian cancer	0.000167	0.00494	CbGpPWpGaD
Bosentan—Back pain—Epirubicin—ovarian cancer	0.000165	0.000514	CcSEcCtD
Bosentan—Angiopathy—Doxorubicin—ovarian cancer	0.000165	0.000512	CcSEcCtD
Bosentan—Muscle spasms—Epirubicin—ovarian cancer	0.000164	0.000511	CcSEcCtD
Bosentan—Immune system disorder—Doxorubicin—ovarian cancer	0.000164	0.00051	CcSEcCtD
Bosentan—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000164	0.000509	CcSEcCtD
Bosentan—Abdominal pain—Docetaxel—ovarian cancer	0.000163	0.000508	CcSEcCtD
Bosentan—Body temperature increased—Docetaxel—ovarian cancer	0.000163	0.000508	CcSEcCtD
Bosentan—Chills—Doxorubicin—ovarian cancer	0.000163	0.000507	CcSEcCtD
Bosentan—Dizziness—Paclitaxel—ovarian cancer	0.000161	0.000502	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—BCL9—ovarian cancer	0.000161	0.00479	CbGpPWpGaD
Bosentan—Vision blurred—Epirubicin—ovarian cancer	0.000161	0.000501	CcSEcCtD
Bosentan—Mental disorder—Doxorubicin—ovarian cancer	0.000159	0.000495	CcSEcCtD
Bosentan—Malnutrition—Doxorubicin—ovarian cancer	0.000158	0.000492	CcSEcCtD
Bosentan—Erythema—Doxorubicin—ovarian cancer	0.000158	0.000492	CcSEcCtD
Bosentan—Anaemia—Epirubicin—ovarian cancer	0.000158	0.000491	CcSEcCtD
Bosentan—Flatulence—Doxorubicin—ovarian cancer	0.000156	0.000485	CcSEcCtD
Bosentan—Vomiting—Paclitaxel—ovarian cancer	0.000155	0.000482	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6ST—ovarian cancer	0.000154	0.00458	CbGpPWpGaD
Bosentan—Rash—Paclitaxel—ovarian cancer	0.000154	0.000478	CcSEcCtD
Bosentan—Dermatitis—Paclitaxel—ovarian cancer	0.000154	0.000478	CcSEcCtD
Bosentan—Vertigo—Epirubicin—ovarian cancer	0.000154	0.000477	CcSEcCtD
Bosentan—Syncope—Epirubicin—ovarian cancer	0.000153	0.000477	CcSEcCtD
Bosentan—Leukopenia—Epirubicin—ovarian cancer	0.000153	0.000476	CcSEcCtD
Bosentan—Back pain—Doxorubicin—ovarian cancer	0.000153	0.000476	CcSEcCtD
Bosentan—Headache—Paclitaxel—ovarian cancer	0.000153	0.000475	CcSEcCtD
Bosentan—Hypersensitivity—Docetaxel—ovarian cancer	0.000152	0.000474	CcSEcCtD
Bosentan—Muscle spasms—Doxorubicin—ovarian cancer	0.000152	0.000473	CcSEcCtD
Bosentan—EDNRA—Endothelins—AKT1—ovarian cancer	0.000151	0.00449	CbGpPWpGaD
Bosentan—Palpitations—Epirubicin—ovarian cancer	0.000151	0.00047	CcSEcCtD
Bosentan—Loss of consciousness—Epirubicin—ovarian cancer	0.00015	0.000467	CcSEcCtD
Bosentan—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000149	0.00443	CbGpPWpGaD
Bosentan—Cough—Epirubicin—ovarian cancer	0.000149	0.000464	CcSEcCtD
Bosentan—Vision blurred—Doxorubicin—ovarian cancer	0.000149	0.000463	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000148	0.00441	CbGpPWpGaD
Bosentan—Asthenia—Docetaxel—ovarian cancer	0.000148	0.000461	CcSEcCtD
Bosentan—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000147	0.00437	CbGpPWpGaD
Bosentan—Pruritus—Docetaxel—ovarian cancer	0.000146	0.000455	CcSEcCtD
Bosentan—Anaemia—Doxorubicin—ovarian cancer	0.000146	0.000454	CcSEcCtD
Bosentan—Arthralgia—Epirubicin—ovarian cancer	0.000146	0.000452	CcSEcCtD
Bosentan—Chest pain—Epirubicin—ovarian cancer	0.000146	0.000452	CcSEcCtD
Bosentan—Anxiety—Epirubicin—ovarian cancer	0.000145	0.000451	CcSEcCtD
Bosentan—Nausea—Paclitaxel—ovarian cancer	0.000145	0.000451	CcSEcCtD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000145	0.000449	CcSEcCtD
Bosentan—Discomfort—Epirubicin—ovarian cancer	0.000144	0.000447	CcSEcCtD
Bosentan—Dry mouth—Epirubicin—ovarian cancer	0.000142	0.000442	CcSEcCtD
Bosentan—Vertigo—Doxorubicin—ovarian cancer	0.000142	0.000442	CcSEcCtD
Bosentan—Syncope—Doxorubicin—ovarian cancer	0.000142	0.000441	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—DLC1—ovarian cancer	0.000142	0.0042	CbGpPWpGaD
Bosentan—Leukopenia—Doxorubicin—ovarian cancer	0.000142	0.00044	CcSEcCtD
Bosentan—Diarrhoea—Docetaxel—ovarian cancer	0.000141	0.00044	CcSEcCtD
Bosentan—Palpitations—Doxorubicin—ovarian cancer	0.00014	0.000435	CcSEcCtD
Bosentan—Oedema—Epirubicin—ovarian cancer	0.000139	0.000434	CcSEcCtD
Bosentan—Anaphylactic shock—Epirubicin—ovarian cancer	0.000139	0.000434	CcSEcCtD
Bosentan—Loss of consciousness—Doxorubicin—ovarian cancer	0.000139	0.000432	CcSEcCtD
Bosentan—Infection—Epirubicin—ovarian cancer	0.000139	0.000431	CcSEcCtD
Bosentan—Cough—Doxorubicin—ovarian cancer	0.000138	0.000429	CcSEcCtD
Bosentan—Shock—Epirubicin—ovarian cancer	0.000137	0.000427	CcSEcCtD
Bosentan—Nervous system disorder—Epirubicin—ovarian cancer	0.000137	0.000425	CcSEcCtD
Bosentan—Dizziness—Docetaxel—ovarian cancer	0.000137	0.000425	CcSEcCtD
Bosentan—Thrombocytopenia—Epirubicin—ovarian cancer	0.000137	0.000425	CcSEcCtD
Bosentan—Tachycardia—Epirubicin—ovarian cancer	0.000136	0.000423	CcSEcCtD
Bosentan—Skin disorder—Epirubicin—ovarian cancer	0.000135	0.000421	CcSEcCtD
Bosentan—Hyperhidrosis—Epirubicin—ovarian cancer	0.000135	0.000419	CcSEcCtD
Bosentan—Chest pain—Doxorubicin—ovarian cancer	0.000135	0.000419	CcSEcCtD
Bosentan—Arthralgia—Doxorubicin—ovarian cancer	0.000135	0.000419	CcSEcCtD
Bosentan—Anxiety—Doxorubicin—ovarian cancer	0.000134	0.000417	CcSEcCtD
Bosentan—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000134	0.00398	CbGpPWpGaD
Bosentan—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000134	0.000416	CcSEcCtD
Bosentan—Discomfort—Doxorubicin—ovarian cancer	0.000133	0.000414	CcSEcCtD
Bosentan—Anorexia—Epirubicin—ovarian cancer	0.000133	0.000413	CcSEcCtD
Bosentan—Dry mouth—Doxorubicin—ovarian cancer	0.000132	0.000409	CcSEcCtD
Bosentan—Vomiting—Docetaxel—ovarian cancer	0.000131	0.000409	CcSEcCtD
Bosentan—Rash—Docetaxel—ovarian cancer	0.00013	0.000405	CcSEcCtD
Bosentan—Hypotension—Epirubicin—ovarian cancer	0.00013	0.000405	CcSEcCtD
Bosentan—Dermatitis—Docetaxel—ovarian cancer	0.00013	0.000405	CcSEcCtD
Bosentan—Headache—Docetaxel—ovarian cancer	0.00013	0.000403	CcSEcCtD
Bosentan—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000129	0.000401	CcSEcCtD
Bosentan—Oedema—Doxorubicin—ovarian cancer	0.000129	0.000401	CcSEcCtD
Bosentan—Infection—Doxorubicin—ovarian cancer	0.000128	0.000399	CcSEcCtD
Bosentan—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—ovarian cancer	0.000128	0.00379	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—DOK1—ovarian cancer	0.000127	0.00378	CbGpPWpGaD
Bosentan—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000127	0.000395	CcSEcCtD
Bosentan—Shock—Doxorubicin—ovarian cancer	0.000127	0.000395	CcSEcCtD
Bosentan—Nervous system disorder—Doxorubicin—ovarian cancer	0.000127	0.000394	CcSEcCtD
Bosentan—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000126	0.000393	CcSEcCtD
Bosentan—Insomnia—Epirubicin—ovarian cancer	0.000126	0.000392	CcSEcCtD
Bosentan—Tachycardia—Doxorubicin—ovarian cancer	0.000126	0.000392	CcSEcCtD
Bosentan—Skin disorder—Doxorubicin—ovarian cancer	0.000125	0.00039	CcSEcCtD
Bosentan—Paraesthesia—Epirubicin—ovarian cancer	0.000125	0.000389	CcSEcCtD
Bosentan—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000125	0.000388	CcSEcCtD
Bosentan—Dyspnoea—Epirubicin—ovarian cancer	0.000124	0.000387	CcSEcCtD
Bosentan—Somnolence—Epirubicin—ovarian cancer	0.000124	0.000386	CcSEcCtD
Bosentan—Anorexia—Doxorubicin—ovarian cancer	0.000123	0.000383	CcSEcCtD
Bosentan—Nausea—Docetaxel—ovarian cancer	0.000123	0.000382	CcSEcCtD
Bosentan—Dyspepsia—Epirubicin—ovarian cancer	0.000123	0.000382	CcSEcCtD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—ovarian cancer	0.000122	0.00363	CbGpPWpGaD
Bosentan—CYP3A4—Tryptophan metabolism—CYP1B1—ovarian cancer	0.000122	0.00361	CbGpPWpGaD
Bosentan—Decreased appetite—Epirubicin—ovarian cancer	0.000121	0.000377	CcSEcCtD
Bosentan—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000121	0.00359	CbGpPWpGaD
Bosentan—Hypotension—Doxorubicin—ovarian cancer	0.000121	0.000375	CcSEcCtD
Bosentan—EDNRA—Peptide ligand-binding receptors—CXCL8—ovarian cancer	0.000121	0.00358	CbGpPWpGaD
Bosentan—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.00012	0.000374	CcSEcCtD
Bosentan—Fatigue—Epirubicin—ovarian cancer	0.00012	0.000374	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—PPP1CC—ovarian cancer	0.00012	0.00356	CbGpPWpGaD
Bosentan—Pain—Epirubicin—ovarian cancer	0.000119	0.000371	CcSEcCtD
Bosentan—Constipation—Epirubicin—ovarian cancer	0.000119	0.000371	CcSEcCtD
Bosentan—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000118	0.000366	CcSEcCtD
Bosentan—ABCB11—Metabolism—NME2—ovarian cancer	0.000117	0.00348	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—ovarian cancer	0.000117	0.00348	CbGpPWpGaD
Bosentan—Insomnia—Doxorubicin—ovarian cancer	0.000117	0.000363	CcSEcCtD
Bosentan—Paraesthesia—Doxorubicin—ovarian cancer	0.000116	0.00036	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—BCL9—ovarian cancer	0.000115	0.00343	CbGpPWpGaD
Bosentan—Dyspnoea—Doxorubicin—ovarian cancer	0.000115	0.000358	CcSEcCtD
Bosentan—Somnolence—Doxorubicin—ovarian cancer	0.000115	0.000357	CcSEcCtD
Bosentan—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000114	0.000355	CcSEcCtD
Bosentan—Dyspepsia—Doxorubicin—ovarian cancer	0.000114	0.000353	CcSEcCtD
Bosentan—EDNRB—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	0.000113	0.00335	CbGpPWpGaD
Bosentan—Decreased appetite—Doxorubicin—ovarian cancer	0.000112	0.000349	CcSEcCtD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—ovarian cancer	0.000112	0.00331	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—ovarian cancer	0.000112	0.00331	CbGpPWpGaD
Bosentan—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000111	0.000346	CcSEcCtD
Bosentan—Fatigue—Doxorubicin—ovarian cancer	0.000111	0.000346	CcSEcCtD
Bosentan—Urticaria—Epirubicin—ovarian cancer	0.000111	0.000345	CcSEcCtD
Bosentan—Pain—Doxorubicin—ovarian cancer	0.00011	0.000343	CcSEcCtD
Bosentan—Constipation—Doxorubicin—ovarian cancer	0.00011	0.000343	CcSEcCtD
Bosentan—Abdominal pain—Epirubicin—ovarian cancer	0.00011	0.000343	CcSEcCtD
Bosentan—Body temperature increased—Epirubicin—ovarian cancer	0.00011	0.000343	CcSEcCtD
Bosentan—EDNRB—G alpha (q) signalling events—PIK3CA—ovarian cancer	0.000108	0.00321	CbGpPWpGaD
Bosentan—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000106	0.000328	CcSEcCtD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—ovarian cancer	0.000105	0.00313	CbGpPWpGaD
Bosentan—Hypersensitivity—Epirubicin—ovarian cancer	0.000103	0.00032	CcSEcCtD
Bosentan—Urticaria—Doxorubicin—ovarian cancer	0.000103	0.000319	CcSEcCtD
Bosentan—Abdominal pain—Doxorubicin—ovarian cancer	0.000102	0.000317	CcSEcCtD
Bosentan—Body temperature increased—Doxorubicin—ovarian cancer	0.000102	0.000317	CcSEcCtD
Bosentan—Asthenia—Epirubicin—ovarian cancer	0.0001	0.000311	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	9.96e-05	0.00295	CbGpPWpGaD
Bosentan—Pruritus—Epirubicin—ovarian cancer	9.87e-05	0.000307	CcSEcCtD
Bosentan—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	9.84e-05	0.00292	CbGpPWpGaD
Bosentan—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	9.71e-05	0.00288	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—ovarian cancer	9.68e-05	0.00287	CbGpPWpGaD
Bosentan—Diarrhoea—Epirubicin—ovarian cancer	9.54e-05	0.000297	CcSEcCtD
Bosentan—Hypersensitivity—Doxorubicin—ovarian cancer	9.51e-05	0.000296	CcSEcCtD
Bosentan—Asthenia—Doxorubicin—ovarian cancer	9.26e-05	0.000288	CcSEcCtD
Bosentan—Dizziness—Epirubicin—ovarian cancer	9.22e-05	0.000287	CcSEcCtD
Bosentan—Pruritus—Doxorubicin—ovarian cancer	9.13e-05	0.000284	CcSEcCtD
Bosentan—EDNRA—Signaling Pathways—DOK1—ovarian cancer	9.12e-05	0.00271	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HDAC6—ovarian cancer	9.08e-05	0.0027	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—PPP2R1A—ovarian cancer	8.96e-05	0.00266	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	8.96e-05	0.00266	CbGpPWpGaD
Bosentan—Vomiting—Epirubicin—ovarian cancer	8.87e-05	0.000276	CcSEcCtD
Bosentan—Diarrhoea—Doxorubicin—ovarian cancer	8.83e-05	0.000275	CcSEcCtD
Bosentan—Rash—Epirubicin—ovarian cancer	8.79e-05	0.000273	CcSEcCtD
Bosentan—Dermatitis—Epirubicin—ovarian cancer	8.79e-05	0.000273	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—ovarian cancer	8.76e-05	0.0026	CbGpPWpGaD
Bosentan—Headache—Epirubicin—ovarian cancer	8.74e-05	0.000272	CcSEcCtD
Bosentan—EDNRB—GPCR ligand binding—CXCL8—ovarian cancer	8.61e-05	0.00255	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PPP1CC—ovarian cancer	8.58e-05	0.00255	CbGpPWpGaD
Bosentan—EDNRB—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	8.57e-05	0.00254	CbGpPWpGaD
Bosentan—Dizziness—Doxorubicin—ovarian cancer	8.53e-05	0.000265	CcSEcCtD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK3—ovarian cancer	8.39e-05	0.00249	CbGpPWpGaD
Bosentan—Nausea—Epirubicin—ovarian cancer	8.29e-05	0.000258	CcSEcCtD
Bosentan—Vomiting—Doxorubicin—ovarian cancer	8.21e-05	0.000255	CcSEcCtD
Bosentan—Rash—Doxorubicin—ovarian cancer	8.14e-05	0.000253	CcSEcCtD
Bosentan—Dermatitis—Doxorubicin—ovarian cancer	8.13e-05	0.000253	CcSEcCtD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	8.12e-05	0.00241	CbGpPWpGaD
Bosentan—EDNRA—Class A/1 (Rhodopsin-like receptors)—CXCL8—ovarian cancer	8.09e-05	0.0024	CbGpPWpGaD
Bosentan—Headache—Doxorubicin—ovarian cancer	8.09e-05	0.000251	CcSEcCtD
Bosentan—EDNRB—Signaling Pathways—YAP1—ovarian cancer	8.04e-05	0.00239	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—ovarian cancer	7.98e-05	0.00237	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—ovarian cancer	7.98e-05	0.00237	CbGpPWpGaD
Bosentan—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	7.98e-05	0.00237	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—XIAP—ovarian cancer	7.88e-05	0.00234	CbGpPWpGaD
Bosentan—EDNRA—G alpha (q) signalling events—PIK3CA—ovarian cancer	7.75e-05	0.0023	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—SMARCA4—ovarian cancer	7.67e-05	0.00228	CbGpPWpGaD
Bosentan—Nausea—Doxorubicin—ovarian cancer	7.67e-05	0.000238	CcSEcCtD
Bosentan—ABCB11—Metabolism—CYTB—ovarian cancer	7.56e-05	0.00224	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—ovarian cancer	7.54e-05	0.00224	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EREG—ovarian cancer	7.49e-05	0.00222	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	7.39e-05	0.00219	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PGR—ovarian cancer	7.02e-05	0.00208	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—ovarian cancer	6.93e-05	0.00206	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PPP1CC—ovarian cancer	6.61e-05	0.00196	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—BRIP1—ovarian cancer	6.61e-05	0.00196	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—PIK3CG—ovarian cancer	6.6e-05	0.00196	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PARP1—ovarian cancer	6.53e-05	0.00194	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HDAC6—ovarian cancer	6.5e-05	0.00193	CbGpPWpGaD
Bosentan—CYP2C9—Biological oxidations—CYP1B1—ovarian cancer	6.43e-05	0.00191	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PPP2R1A—ovarian cancer	6.41e-05	0.0019	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—ovarian cancer	6.41e-05	0.0019	CbGpPWpGaD
Bosentan—CYP2C9—Metapathway biotransformation—CYP1B1—ovarian cancer	6.34e-05	0.00188	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—IL6ST—ovarian cancer	6.24e-05	0.00185	CbGpPWpGaD
Bosentan—EDNRA—GPCR ligand binding—CXCL8—ovarian cancer	6.16e-05	0.00183	CbGpPWpGaD
Bosentan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—ovarian cancer	6.14e-05	0.00182	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—PIK3CG—ovarian cancer	6e-05	0.00178	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—PIK3CD—ovarian cancer	5.81e-05	0.00172	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—YAP1—ovarian cancer	5.75e-05	0.00171	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—XIAP—ovarian cancer	5.64e-05	0.00167	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—SMARCA4—ovarian cancer	5.49e-05	0.00163	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EREG—ovarian cancer	5.36e-05	0.00159	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PPP2R1A—ovarian cancer	5.29e-05	0.00157	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—PIK3CD—ovarian cancer	5.27e-05	0.00156	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—PIK3CB—ovarian cancer	5.06e-05	0.0015	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PGR—ovarian cancer	5.02e-05	0.00149	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	4.96e-05	0.00147	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—CXCL8—ovarian cancer	4.86e-05	0.00144	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	4.82e-05	0.00143	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—PIK3CG—ovarian cancer	4.73e-05	0.0014	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PARP1—ovarian cancer	4.67e-05	0.00139	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—IL2—ovarian cancer	4.65e-05	0.00138	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—PIK3CB—ovarian cancer	4.6e-05	0.00136	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—IL6ST—ovarian cancer	4.47e-05	0.00133	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—YAP1—ovarian cancer	4.43e-05	0.00132	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—CXCL8—ovarian cancer	4.42e-05	0.00131	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	4.39e-05	0.0013	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PIK3CG—ovarian cancer	4.29e-05	0.00127	CbGpPWpGaD
Bosentan—CYP3A4—Biological oxidations—CYP1B1—ovarian cancer	4.24e-05	0.00126	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—IL2—ovarian cancer	4.22e-05	0.00125	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TERT—ovarian cancer	4.21e-05	0.00125	CbGpPWpGaD
Bosentan—CYP3A4—Metapathway biotransformation—CYP1B1—ovarian cancer	4.18e-05	0.00124	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—PIK3CD—ovarian cancer	4.16e-05	0.00123	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—NME2—ovarian cancer	3.92e-05	0.00116	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CAV1—ovarian cancer	3.89e-05	0.00115	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	3.86e-05	0.00114	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PPP2R1A—ovarian cancer	3.79e-05	0.00112	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PIK3CD—ovarian cancer	3.77e-05	0.00112	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ESR1—ovarian cancer	3.75e-05	0.00111	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL6ST—ovarian cancer	3.69e-05	0.00109	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—PIK3CB—ovarian cancer	3.62e-05	0.00108	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—FASN—ovarian cancer	3.61e-05	0.00107	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—SLC5A5—ovarian cancer	3.56e-05	0.00106	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—APC—ovarian cancer	3.54e-05	0.00105	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PIK3CG—ovarian cancer	3.54e-05	0.00105	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—NRAS—ovarian cancer	3.54e-05	0.00105	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—CXCL8—ovarian cancer	3.48e-05	0.00103	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—SLC2A1—ovarian cancer	3.43e-05	0.00102	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—MAPK3—ovarian cancer	3.39e-05	0.00101	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	3.36e-05	0.000998	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—IL2—ovarian cancer	3.33e-05	0.000987	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	3.32e-05	0.000987	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CYP1B1—ovarian cancer	3.29e-05	0.000977	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PIK3CB—ovarian cancer	3.29e-05	0.000976	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—MAPK1—ovarian cancer	3.23e-05	0.000958	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—EGFR—ovarian cancer	3.23e-05	0.000958	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—CXCL8—ovarian cancer	3.16e-05	0.000938	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PIK3CD—ovarian cancer	3.11e-05	0.000924	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—PIK3CA—ovarian cancer	3.09e-05	0.000916	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—KRAS—ovarian cancer	3.05e-05	0.000905	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—IL2—ovarian cancer	3.02e-05	0.000897	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TERT—ovarian cancer	3.01e-05	0.000893	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PPP2R1A—ovarian cancer	2.92e-05	0.000867	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	2.91e-05	0.000862	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—PIK3CA—ovarian cancer	2.8e-05	0.000832	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CAV1—ovarian cancer	2.78e-05	0.000826	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—ERBB2—ovarian cancer	2.75e-05	0.000817	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PIK3CB—ovarian cancer	2.71e-05	0.000806	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MTOR—ovarian cancer	2.71e-05	0.000806	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—ABCB1—ovarian cancer	2.71e-05	0.000805	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	2.71e-05	0.000804	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ESR1—ovarian cancer	2.68e-05	0.000796	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—TYMS—ovarian cancer	2.66e-05	0.00079	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL6ST—ovarian cancer	2.64e-05	0.000783	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CXCL8—ovarian cancer	2.61e-05	0.000774	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—HRAS—ovarian cancer	2.59e-05	0.000769	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—NME2—ovarian cancer	2.58e-05	0.000767	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CDKN1B—ovarian cancer	2.55e-05	0.000756	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CG—ovarian cancer	2.54e-05	0.000753	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—APC—ovarian cancer	2.54e-05	0.000753	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—NRAS—ovarian cancer	2.54e-05	0.000753	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYTB—ovarian cancer	2.53e-05	0.000749	CbGpPWpGaD
Bosentan—EDNRB—GPCR downstream signaling—AKT1—ovarian cancer	2.52e-05	0.000748	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CASP3—ovarian cancer	2.5e-05	0.000741	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL2—ovarian cancer	2.49e-05	0.00074	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—IL6—ovarian cancer	2.48e-05	0.000736	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	2.47e-05	0.000732	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CCND1—ovarian cancer	2.43e-05	0.000721	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—MAPK3—ovarian cancer	2.43e-05	0.000721	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—CTNNB1—ovarian cancer	2.41e-05	0.000714	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MMP9—ovarian cancer	2.36e-05	0.0007	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PTEN—ovarian cancer	2.35e-05	0.000696	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—MAPK1—ovarian cancer	2.31e-05	0.000686	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—EGFR—ovarian cancer	2.31e-05	0.000686	CbGpPWpGaD
Bosentan—EDNRB—Signaling by GPCR—AKT1—ovarian cancer	2.29e-05	0.000679	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CD—ovarian cancer	2.23e-05	0.000662	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—PIK3CA—ovarian cancer	2.21e-05	0.000655	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PPP1CC—ovarian cancer	2.21e-05	0.000655	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—BRIP1—ovarian cancer	2.21e-05	0.000655	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—KRAS—ovarian cancer	2.18e-05	0.000648	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—CAV1—ovarian cancer	2.15e-05	0.000637	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—VEGFA—ovarian cancer	2.12e-05	0.000629	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—STAT3—ovarian cancer	2.1e-05	0.000623	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—NRAS—ovarian cancer	2.09e-05	0.000621	CbGpPWpGaD
Bosentan—ABCB11—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	2.05e-05	0.000608	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—PIK3CA—ovarian cancer	2.01e-05	0.000595	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MAPK3—ovarian cancer	2e-05	0.000595	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—ERBB2—ovarian cancer	1.97e-05	0.000584	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CG—ovarian cancer	1.95e-05	0.00058	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MYC—ovarian cancer	1.95e-05	0.000579	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MTOR—ovarian cancer	1.94e-05	0.000577	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CB—ovarian cancer	1.94e-05	0.000577	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—MAPK1—ovarian cancer	1.91e-05	0.000566	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—EGFR—ovarian cancer	1.91e-05	0.000566	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CXCL8—ovarian cancer	1.87e-05	0.000554	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—HRAS—ovarian cancer	1.86e-05	0.000551	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CDKN1B—ovarian cancer	1.82e-05	0.000541	CbGpPWpGaD
Bosentan—EDNRA—GPCR downstream signaling—AKT1—ovarian cancer	1.8e-05	0.000535	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—KRAS—ovarian cancer	1.8e-05	0.000535	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CASP3—ovarian cancer	1.79e-05	0.00053	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL2—ovarian cancer	1.78e-05	0.00053	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—IL6—ovarian cancer	1.78e-05	0.000527	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CCND1—ovarian cancer	1.74e-05	0.000516	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—CTNNB1—ovarian cancer	1.72e-05	0.000511	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CD—ovarian cancer	1.72e-05	0.00051	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MMP9—ovarian cancer	1.69e-05	0.000501	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PTEN—ovarian cancer	1.68e-05	0.000498	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYTB—ovarian cancer	1.67e-05	0.000494	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—PIK3CA—ovarian cancer	1.65e-05	0.000491	CbGpPWpGaD
Bosentan—EDNRA—Signaling by GPCR—AKT1—ovarian cancer	1.64e-05	0.000486	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	1.61e-05	0.000477	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—TP53—ovarian cancer	1.6e-05	0.000475	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—HRAS—ovarian cancer	1.53e-05	0.000454	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—VEGFA—ovarian cancer	1.52e-05	0.00045	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—STAT3—ovarian cancer	1.5e-05	0.000446	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—NRAS—ovarian cancer	1.5e-05	0.000445	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CB—ovarian cancer	1.5e-05	0.000444	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—YAP1—ovarian cancer	1.48e-05	0.000439	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—IL6—ovarian cancer	1.47e-05	0.000435	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	1.46e-05	0.000435	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PPP1CC—ovarian cancer	1.46e-05	0.000432	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—BRIP1—ovarian cancer	1.46e-05	0.000432	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MAPK3—ovarian cancer	1.43e-05	0.000426	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MYC—ovarian cancer	1.4e-05	0.000414	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—MAPK1—ovarian cancer	1.36e-05	0.000405	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—EGFR—ovarian cancer	1.36e-05	0.000405	CbGpPWpGaD
Bosentan—EDNRB—Signaling Pathways—AKT1—ovarian cancer	1.35e-05	0.000401	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PTEN—ovarian cancer	1.29e-05	0.000384	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—KRAS—ovarian cancer	1.29e-05	0.000383	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	1.29e-05	0.000382	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—FASN—ovarian cancer	1.21e-05	0.000358	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC5A5—ovarian cancer	1.19e-05	0.000352	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—PIK3CA—ovarian cancer	1.18e-05	0.000352	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—SLC2A1—ovarian cancer	1.15e-05	0.00034	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—TP53—ovarian cancer	1.15e-05	0.00034	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	1.12e-05	0.000333	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CYP1B1—ovarian cancer	1.1e-05	0.000326	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—HRAS—ovarian cancer	1.1e-05	0.000325	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—IL6—ovarian cancer	1.05e-05	0.000311	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—YAP1—ovarian cancer	9.76e-06	0.00029	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PPP2R1A—ovarian cancer	9.75e-06	0.000289	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	9.7e-06	0.000288	CbGpPWpGaD
Bosentan—EDNRA—Signaling Pathways—AKT1—ovarian cancer	9.68e-06	0.000287	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—PIK3CA—ovarian cancer	9.13e-06	0.000271	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—ABCB1—ovarian cancer	9.05e-06	0.000269	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—TYMS—ovarian cancer	8.89e-06	0.000264	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—FASN—ovarian cancer	7.96e-06	0.000236	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC5A5—ovarian cancer	7.83e-06	0.000232	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—SLC2A1—ovarian cancer	7.56e-06	0.000224	CbGpPWpGaD
Bosentan—ABCB11—Metabolism—AKT1—ovarian cancer	7.46e-06	0.000221	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CYP1B1—ovarian cancer	7.25e-06	0.000215	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—CAV1—ovarian cancer	7.16e-06	0.000213	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	6.84e-06	0.000203	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CG—ovarian cancer	6.52e-06	0.000194	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	6.43e-06	0.000191	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—ABCB1—ovarian cancer	5.97e-06	0.000177	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—TYMS—ovarian cancer	5.86e-06	0.000174	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CD—ovarian cancer	5.74e-06	0.00017	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CB—ovarian cancer	5e-06	0.000148	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—CAV1—ovarian cancer	4.72e-06	0.00014	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PTEN—ovarian cancer	4.32e-06	0.000128	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CG—ovarian cancer	4.3e-06	0.000128	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CD—ovarian cancer	3.78e-06	0.000112	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CB—ovarian cancer	3.3e-06	9.79e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—PIK3CA—ovarian cancer	3.05e-06	9.05e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PTEN—ovarian cancer	2.85e-06	8.46e-05	CbGpPWpGaD
Bosentan—CYP2C9—Metabolism—AKT1—ovarian cancer	2.49e-06	7.39e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—PIK3CA—ovarian cancer	2.01e-06	5.97e-05	CbGpPWpGaD
Bosentan—CYP3A4—Metabolism—AKT1—ovarian cancer	1.64e-06	4.87e-05	CbGpPWpGaD
